TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29?? Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually. Poster Presentation Details: Title: Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation Authors: Hannah L Bader, Kostadin P Petrov, Stephen Carroll, Debanjan Goswamy, Nivya Sharma, Shubhangi Kamalia, Daniel Pollacksmith, Drashti Sha, Kenneth L Jahan, Ryan E Kritzer, Hana Husic, Shobhita Jillella, Nicole Ladd, Jackson Lirette, Shoshana Bloom, Prachi Dhanania, Lisa Fleischer, Chandan K Pavuluri, Tyler M Sinacola,
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics (TCRX) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- TScan Therapeutics (TCRX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TCRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- TScan Therapeutics (TCRX) had its price target raised by Wedbush from $4.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
TCRX
Earnings
- 8/12/25 - In-Line
TCRX
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEF
- 4/7/26 - Form PRE
- TCRX's page on the SEC website